$DRMA
Dermata Therapeutics, Inc.

2022 Q2 Form 10-Q Financial Statement

#000165495422006966 Filed on May 16, 2022

View on sec.gov

Income Statement

Concept 2022 Q2 2022 Q1 2021 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.118M $1.190M $1.581M
YoY Change 141.59% -24.72% 305.43%
% of Gross Profit
Research & Development $1.613M $1.596M $680.6K
YoY Change 85.95% 134.48% -29.11%
% of Gross Profit
Depreciation & Amortization $0.00
YoY Change
% of Gross Profit
Operating Expenses $1.613M $1.596M $680.6K
YoY Change 85.95% 134.48% -49.59%
Operating Profit -$2.731M -$2.786M -$2.262M
YoY Change 105.31% 23.18%
Interest Expense $0.00 $0.00 $43.14K
YoY Change -100.0% -100.0% -161.62%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$2.731M -$2.786M -$2.305M
YoY Change 105.03% 20.88% 62.32%
Income Tax
% Of Pretax Income
Net Earnings -$2.731M -$2.786M -$2.305M
YoY Change 105.03% 20.88% 62.18%
Net Earnings / Revenue
Basic Earnings Per Share -$3.90 -$0.33 -$1.21
Diluted Earnings Per Share -$243.9K -$333.6K -$276.7K
COMMON SHARES
Basic Shares Outstanding 9.227M shares 8.352M shares 1.911M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q2 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.63M $8.191M $1.330M
YoY Change 2387.8% 515.67%
Cash & Equivalents $10.63M $8.191M
Short-Term Investments
Other Short-Term Assets $398.5K $853.1K $320.8K
YoY Change -43.84% 165.93%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $11.03M $9.044M $1.651M
YoY Change 869.9% 447.73%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets -$2.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $11.03M $9.044M $1.651M
Total Long-Term Assets -$2.00 $0.00 $0.00
Total Assets $11.03M $9.044M $1.651M
YoY Change 869.9% 447.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $608.8K $662.2K $488.1K
YoY Change -30.92% 35.68%
Accrued Expenses $757.7K $529.3K $276.3K
YoY Change 29.18% 91.54%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $174.8K
YoY Change -100.0% -100.0%
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $1.366M $1.192M $939.2K
YoY Change -16.81% 26.87%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.366M $1.192M $939.2K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.366M $1.192M $939.2K
YoY Change -16.81% 26.87%
SHAREHOLDERS EQUITY
Retained Earnings -$41.50M
YoY Change 30.84%
Common Stock $1.010K
YoY Change 428.8%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.660M $7.853M $712.0K
YoY Change
Total Liabilities & Shareholders Equity $11.03M $9.044M $1.651M
YoY Change 869.9% 447.73%

Cashflow Statement

Concept 2022 Q2 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$2.731M -$2.786M -$2.305M
YoY Change 105.03% 20.88% 62.18%
Depreciation, Depletion And Amortization $0.00
YoY Change
Cash From Operating Activities -$1.840M -$2.608M -$776.2K
YoY Change 103.66% 235.97% -43.75%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.276M $0.00 $1.576M
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -1.840M -2.608M -776.2K
Cash From Investing Activities
Cash From Financing Activities 4.276M $0.00 $1.576M
Net Change In Cash 2.437M $0.00 $1.576M
YoY Change -369.81% -100.0% -214.22%
FREE CASH FLOW
Cash From Operating Activities -$1.840M -$2.608M -$776.2K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
9227214 shares
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000 shares
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8328629 shares
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1595839 USD
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
680588 USD
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1190313 USD
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1581185 USD
CY2021Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
2261773 USD
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2786152 USD
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2261773 USD
CY2022Q1 us-gaap Interest Expense
InterestExpense
0 USD
CY2021Q1 us-gaap Interest Expense
InterestExpense
43135 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2786152 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2304908 USD
CY2022Q1 drma Net Loss Per Share Of Common Stock Basic And Diluted
NetLossPerShareOfCommonStockBasicAndDiluted
-0.33
CY2021Q1 drma Net Loss Per Share Of Common Stock Basic And Diluted
NetLossPerShareOfCommonStockBasicAndDiluted
-1.21
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
10107104 USD
CY2022Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
531566 USD
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-2786151 USD
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
7852519 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-3177939 USD
CY2021Q1 drma Series1d Preferred Units Issued Amount
Series1dPreferredUnitsIssuedAmount
5034801 USD
CY2021Q1 drma Class B Common Units Forfeited Amount
ClassBCommonUnitsForfeitedAmount
0 USD
CY2021Q1 drma Conversion Of Common Units To Common Stock Amount
ConversionOfCommonUnitsToCommonStockAmount
0 USD
CY2021Q1 drma Conversion Of Preferred Units To Preferred Stock Amount
ConversionOfPreferredUnitsToPreferredStockAmount
0 USD
CY2021Q1 drma Conversion Of Warrant Units To Preferred Stock Amount
ConversionOfWarrantUnitsToPreferredStockAmount
0 USD
CY2021Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
1160049 USD
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-2304908 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
712003 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
178304 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
1528688 USD
CY2022Q1 us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
0 USD
CY2021Q1 us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
-556482 USD
CY2022Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 USD
CY2021Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1562717 USD
CY2022Q1 drma Proceeds From Issuance Of Series1 D Preferred Units
ProceedsFromIssuanceOfSeries1DPreferredUnits
0 USD
CY2021Q1 drma Proceeds From Issuance Of Series1 D Preferred Units
ProceedsFromIssuanceOfSeries1DPreferredUnits
570000 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1576235 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2607848 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
800015 USD
CY2021Q4 us-gaap Cash
Cash
10798806 USD
CY2020Q4 us-gaap Cash
Cash
530400 USD
CY2022Q1 us-gaap Cash
Cash
8190958 USD
CY2021Q1 us-gaap Cash
Cash
1330415 USD
CY2022Q1 us-gaap Interest Paid
InterestPaid
0 USD
CY2021Q1 us-gaap Interest Paid
InterestPaid
473 USD
CY2022Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
CY2021Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
950 USD
CY2022Q1 drma Conversion Of Convertible Subordinated Promissory Notes To Series1 D Preferred Units
ConversionOfConvertibleSubordinatedPromissoryNotesToSeries1DPreferredUnits
0 USD
CY2021Q1 drma Conversion Of Convertible Subordinated Promissory Notes To Series1 D Preferred Units
ConversionOfConvertibleSubordinatedPromissoryNotesToSeries1DPreferredUnits
4464801 USD
CY2022Q1 drma Conversion Of Common And Preferred Units And Warrants To Common And Preferred Stock And Warrants
ConversionOfCommonAndPreferredUnitsAndWarrantsToCommonAndPreferredStockAndWarrants
0 USD
CY2021Q1 drma Conversion Of Common And Preferred Units And Warrants To Common And Preferred Stock And Warrants
ConversionOfCommonAndPreferredUnitsAndWarrantsToCommonAndPreferredStockAndWarrants
29936660 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Discontinued Operations
NetCashProvidedByUsedInDiscontinuedOperations
2600000 USD
CY2021Q3 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
2571428 shares
CY2021Q3 drma Warrants To Purchase One Share Of Common Stock
WarrantsToPurchaseOneShareOfCommonStock
2957142 shares
CY2021Q3 us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
65823015 shares
CY2021Q3 drma Combined Offering Price
CombinedOfferingPrice
7.00
CY2022Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
7.05
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8328629 shares
CY2022Q1 drma Accumulated Deficit
AccumulatedDeficit
-38800000 USD
CY2021 us-gaap Net Cash Provided By Used In Discontinued Operations
NetCashProvidedByUsedInDiscontinuedOperations
5700000 USD
CY2022Q1 drma Gross Proceeds Of A Securities Purchase Agreement
GrossProceedsOfASecuritiesPurchaseAgreement
5000000.0 USD
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:left;">The Company’s financial statements are prepared in accordance with GAAP. The preparation of the Company’s financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, and expenses and disclosure of contingent assets and liabilities in the financial statements and accompanying notes. On an ongoing basis, management evaluates these estimates and judgments, including those related to accrued research and development expenses, stock-based compensation, and the estimated fair values of equity instruments. Management evaluates its estimates on an ongoing basis. The Company bases its estimates on various assumptions that it believes are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.</p>
CY2022Q1 drma Schedule Of Potentially Dilutive Securities
ScheduleOfPotentiallyDilutiveSecurities
<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months Ended March 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,786,152 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,304,908 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Basic and diluted net loss per common unit/share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(0.33 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1.21 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted-average basic and diluted common units/shares</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">8,352,459</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,911,009</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2786152 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2304908 USD
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.33
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.21
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8352459 shares
CY2022Q1 us-gaap Deferred Offering Costs
DeferredOfferingCosts
2600000 USD
CY2022Q1 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
200000 USD
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1911009 shares
CY2021Q1 drma Series1 Preferred Units Shares
Series1PreferredUnitsShares
336882 shares
CY2021Q1 drma Series1 A Preferred Units Shares
Series1APreferredUnitsShares
244811 shares
CY2021Q1 drma Series1 A Prerferred Warrant Units Shares
Series1APrerferredWarrantUnitsShares
69212 shares
CY2021Q1 drma Series1 B Preferred Units Shares
Series1BPreferredUnitsShares
317058 shares
CY2021Q1 drma Series1 C Preferred Units Shares
Series1CPreferredUnitsShares
2270866 shares
CY2021Q1 drma Series1 D Preferred Units Shares
Series1DPreferredUnitsShares
931265 shares
CY2022Q1 drma Common Stock Options
CommonStockOptions
1001326 shares
CY2021Q1 drma Common Stock Options
CommonStockOptions
398199 shares
CY2022Q1 drma Common Stock Warrants
CommonStockWarrants
3220228 shares
CY2021Q1 drma Common Stock Warrants
CommonStockWarrants
65303 shares
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4221554 shares
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4633596 shares
CY2020Q4 us-gaap Convertible Subordinated Debt
ConvertibleSubordinatedDebt
3000000 USD
CY2020Q4 us-gaap Notes Payable
NotesPayable
1145000 USD
CY2020Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
1730000 USD
CY2020Q4 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
125000 USD
CY2020Q4 us-gaap Subordinated Borrowing Interest Rate
SubordinatedBorrowingInterestRate
0.04 pure
CY2020Q4 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2021-07-17
CY2021Q1 drma Discount Rate For Preferred Shares
DiscountRateForPreferredShares
10000000 USD
CY2021Q1 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2021-12-31
CY2021Q1 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
1255000 USD
CY2021Q1 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
311000 USD
CY2021Q1 us-gaap Debt Instrument Fee Amount
DebtInstrumentFeeAmount
100000 USD
CY2022Q1 drma Payments For Its Long Term Debt
PaymentsForItsLongTermDebt
556482 USD
CY2021Q3 us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
65823015 shares
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8328629 shares
CY2022Q1 drma Common Stock Share Issued
CommonStockShareIssued
6906244 shares
CY2022Q1 drma Preferred Unit Interest Rate
PreferredUnitInterestRate
8
CY2022Q1 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
0.80
CY2021Q2 drma Common Stock Shares Available For Issuances
CommonStockSharesAvailableForIssuances
593340 shares
CY2021Q3 drma Common Stock Shares Available For Issuances
CommonStockSharesAvailableForIssuances
1648213 shares
CY2022Q1 drma Evergreen Provision Resulted In Increase
EvergreenProvisionResultedInIncrease
83286 shares
CY2022Q1 drma Increasing Shares Authorized For Issuance
IncreasingSharesAuthorizedForIssuance
1731499 shares
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000 shares
CY2022Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2957142 shares
CY2020 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
18750 USD
CY2022Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
83286 shares
CY2021Q1 drma Class B Common Units Profits Interests Converted Due To The Conversion From An Llc To Ac Corporation
ClassBCommonUnitsProfitsInterestsConvertedDueToTheConversionFromAnLlcToACCorporation
277448 shares
CY2021Q1 drma Class B Common Units Profits Interests Converted Into Options
ClassBCommonUnitsProfitsInterestsConvertedIntoOptions
277448 shares
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1339993 USD
CY2022Q1 drma Stock Based Compensation Expense
StockBasedCompensationExpense
849564 USD
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P2Y2M12D
CY2021Q1 drma Stock Based Compensation Expense
StockBasedCompensationExpense
400000 USD
CY2022Q1 drma Unrecognized Future Stock Based Compensation Expense
UnrecognizedFutureStockBasedCompensationExpense
1500000 USD
CY2022Q1 drma Expected Lenght Of Recognized Term
ExpectedLenghtOfRecognizedTerm
P2Y8M12D
CY2019Q2 us-gaap Preferred Units Issued
PreferredUnitsIssued
5221156 shares
CY2022Q1 drma Additional Research And Development Expense
AdditionalResearchAndDevelopmentExpense
1100000 USD
CY2021Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
1200000 USD
CY2020 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
1145000 USD
CY2021Q1 us-gaap Convertible Preferred Stock Converted To Other Securities
ConvertiblePreferredStockConvertedToOtherSecurities
1255000 USD
CY2021 us-gaap Dividends Preferred Stock
DividendsPreferredStock
2300000 USD

Files In Submission

Name View Source Status
R8.htm Edgar Link pending
0001654954-22-006966-index-headers.html Edgar Link pending
0001654954-22-006966-index.html Edgar Link pending
0001654954-22-006966.txt Edgar Link pending
0001654954-22-006966-xbrl.zip Edgar Link pending
drma-20220331.xsd Edgar Link pending
drma-20220331_cal.xml Edgar Link unprocessable
drma-20220331_def.xml Edgar Link unprocessable
drma-20220331_lab.xml Edgar Link unprocessable
drma-20220331_pre.xml Edgar Link unprocessable
drma_10q.htm Edgar Link pending
drma_10q_htm.xml Edgar Link completed
drma_ex311.htm Edgar Link pending
drma_ex312.htm Edgar Link pending
drma_ex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending